Number and proportion of glaucoma patients continuing with their first-line therapy after 1, 3, and 5 years of follow-up in the FinHealth 2017 Survey sample representing the Finnish adult population aged 30 years or older according to their first-line glaucoma monotherapy drug class and type during the follow-up between 1995 and 2019.

Number and proportion of glaucoma patients continuing with their first-line therapy after 1, 3, and 5 years of follow-up in the FinHealth 2017 Survey sample representing the Finnish adult population aged 30 years or older according to their first-line glaucoma monotherapy drug class and type during the follow-up between 1995 and 2019.

本数据集统计了1995至2019年随访周期内，以代表芬兰30岁及以上成年人群的芬兰健康2017调查（FinHealth 2017 Survey）样本为研究对象，按照受试者所使用的青光眼一线单药治疗的药物类别与药物类型进行分组，随访1年、3年及5年后仍坚持一线治疗的青光眼患者的人数及占比。